Seattle Genetics Begins Multiple Myeloma Trial

Seattle Genetics has started a Phase Ib trial of SGN-40 in combination with Revlimid and dexamethasone, a steroid, for patients with relapsed or refractory multiple myeloma.

The U.S.-based, multi-site, open-label, single-arm trial will enroll approximately 40 patients, who will receive escalating doses of SGN-40 in combination with Revlimid (lenalidomide) and dexamethasone.

The start of the trial triggers a $4 million milestone payment from Genentech, Seattle Genetics said.